

Leroy A. Richardson,
*Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.*

[FR Doc. 2016-19460 Filed 8-15-16; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC-2016-0083; 60Day-16-
16AWM]

Proposed Data Collection Submitted for Public Comment and Recommendations

AGENCY: Centers for Disease Control and
Prevention, Department of Health and
Human Services.

ACTION: Notice with comment period.

SUMMARY: Centers for Disease Control
and Prevention as part of its continuing
efforts to reduce public burden and
maximize the utility of government
information, invites the general public
and other Federal agencies to take this
opportunity to comment on this
proposed information collections, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on the Executive and
Scientific Resources Office Access
Management System (EAMTS). EAMTS
is designed to house all Guest
Researcher & ORISE program packets,
Appointment Mechanism Determination
Forms, and Title 42 Fellowship
Immigration information in one central
location on the Human Resources Office
SharePoint Server.

DATES: Written comments must be
received on or before October 17, 2016.

ADDRESSES: You may submit comments,
identified by Docket No. CDC-2016-
0083 by any of the following methods:
Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.

Mail: Jeffrey M. Zirger, Acting
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE., MS-
D74, Atlanta, Georgia 30329.

Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to *Regulations.gov*, including any
personal information provided. For
access to the docket to read background
documents or comments received, go to
Regulations.gov.

Note: All public comment should be
submitted through the Federal eRulemaking
portal (*Regulations.gov*) or by U.S. mail to the
address listed above.

FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact the Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE., MS-D74, Atlanta,
Georgia 30329; phone: 404-639-7570;
Email: *omb@cdc.gov*.

SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501-3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the **Federal Register**
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.

Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency's estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology; and (e) estimates of capital
or start-up costs and costs of operation,
maintenance, and purchase of services
to provide information. Burden means
the total time, effort, or financial
resources expended by persons to
generate, maintain, retain, disclose or
provide information to or for a Federal
agency. This includes the time needed
to review instructions; to develop,
acquire, install and utilize technology
and systems for the purpose of
collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information, to search
data sources, to complete and review

the collection of information; and to
transmit or otherwise disclose the
information.

Proposed Project

Data Management for Executive and
Scientific Resources Access
Management Tracking System—New—
Executive and Scientific Resource Office
(ESRO), Centers for Disease Control and
Prevention (CDC).

Background and Brief Description

ESRO seeks to submit and
information collection request for
approval of information collections
through its ESRO Access Management
Tracking System (EAMTS). This system
will automate current manual processes
for programs managed by ESRO. This
new process will provide users a single,
integrated location to allow for
collaboration, faster processing between
the programs and ESRO and a better
onboarding experience for potential
fellows.

EAMTS will support users by
providing a single, integrated location
for enterprise content management,
manage documents and records by using
workflows an information rights
management. This business process will
allow ESRO to design forms that are
accessible in SharePoint through a Web
Browser. Team members will be able to
access critical business information,
analyze and view data, and publish
reports to make more informed
decisions.

EAMTS will allow CIO's to submit
digital packets including Guest
Researcher, ORISE, Title 42 Fellowship
Visa request (portion of CDC 0.1475)
and Appointment Mechanism
Determination Request Form (CDC
0.4601). CIO's can upload supplemental
documentation as an attachment to each
application, electronically track and
monitor status of application, digitally
sign forms and requests, receive case
determinations quickly and accurately,
and track the Visa status of Title 42
Fellowship requests that require Visa
assistance from the Human Resources
Office.

EAMTS is developed in SharePoint
for CDC's Centers/Institutes/Offices
(CIO) to submit required information for
all of Executive and Scientific Resource
Office's managed programs and for these
CIO's to effectively and efficiently
digitally review this information. Data is
managed and maintained by appropriate
CIO Staff with ground and form level
permission.

Permissions to EAMTS are required to
access the lists, forms, and document
library. This includes entering data,

clearing/approving forms, processing forms, and acknowledging data entered.

The total estimated annualized burden hours for all respondents are 1,280. There are no costs to respondents

other than their time. CDC will seek a three-year approval from OMB.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per CIO	Average burden per response (in hours)	Total burden (in hours)
Initiator/C//O	CDC 0.4601	64	5	1	320
Initiator/C//O	CDC 0.410A	64	5	1	320
Initiator/C//O	CDC 0.410B	64	5	1	320
Initiator/C//O	Section C of the CDC 0.1475	64	5	1	320
Totals	1,280

Leroy A. Richardson,

Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.

[FR Doc. 2016–19461 Filed 8–15–16; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation Cooperative Agreement (U01).

Date: September 22, 2016.

Time: 10:00 a.m. to 12:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Room 3F100, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

Contact Person: Lynn Rust, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room 3G42A, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 9823,

Bethesda, MD 20892–9823, (240) 669–5069, lrust@niaid.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: August 10, 2016.

Natasha M. Copeland,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2016–19417 Filed 8–15–16; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: Small Molecule Therapeutic Compounds Encompassed Within the Licensed Patent Rights for the Treatment of Thioesterase Deficiency Disorder

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Evaluation Option License Agreement to practice the inventions embodied in the following Patent Applications to Circumvent Pharmaceuticals Inc. (“Circumvent”) located in Pasadena, California, USA:

Intellectual Property

United States Provisional Patent Application No. 61/473,692, filed April 8, 2011, titled “Small molecule therapeutic compounds targeting thioesterase deficiency disorders and methods of using the same” [HHS

Reference No. E–157–2011/0–US–01], status: Expired;

International Patent Application No. PCT/US2012/32772 filed April 9, 2012 titled “Small molecule therapeutic compounds targeting thioesterase deficiency disorders and methods of using the same” [HHS Reference No. E–157–2011/0–PCT–02], status: Converted;

European Patent Application No. 12716889.6, filed November 7, 2013, titled “Small molecule therapeutic compounds targeting thioesterase deficiency disorders and methods of using the same” [HHS Reference No. E–157–2011/0–EP–03], status: Pending; and

United States Patent Application No. 14/110,393, filed October 7, 2013, titled “Small molecule therapeutic compounds targeting thioesterase deficiency disorders and methods of using the same” [HHS Reference No. E–157–2011/0–US–04], status: Pending.

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The territory of the prospective Start-Up Exclusive Evaluation Option License Agreement may be worldwide and the field of use may be limited to: “Small molecule therapeutic compounds encompassed within the Licensed Patent Rights for the treatment of thioesterase deficiency disorders”

Upon the expiration or termination of the Start-up Exclusive Evaluation Option License Agreement, Circumvent will have the exclusive right to execute a Start-Up Exclusive Patent License Agreement which will supersede and replace the Start-up Exclusive Evaluation Option License Agreement, with no greater field of use and territory than granted in the Start-up Exclusive Evaluation Option License Agreement.

DATES: Only written comments and/or applications for a license which are received by the NIH Office of